Inhibrx Biosciences Files 8-K

Ticker: INBX · Form: 8-K · Filed: Jun 17, 2024 · CIK: 2007919

Inhibrx Biosciences, Inc. 8-K Filing Summary
FieldDetail
CompanyInhibrx Biosciences, Inc. (INBX)
Form Type8-K
Filed DateJun 17, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: filing, regulatory-disclosure, financials

TL;DR

Inhibrx filed an 8-K, likely routine updates on regs and financials.

AI Summary

On June 17, 2024, Inhibrx Biosciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. There are no specific material events or financial figures detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates that Inhibrx Biosciences, Inc. is providing updates related to regulatory disclosures and financial information to the SEC.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing header and does not contain information about material events, financial performance, or significant business changes.

Key Players & Entities

  • Inhibrx Biosciences, Inc. (company) — Registrant
  • 0002007919-24-000016 (other) — Accession Number
  • June 17, 2024 (date) — Date of Report
  • Delaware (location) — State of Incorporation
  • 11025 N. Torrey Pines Road, Suite 140 (address) — Principal Executive Offices
  • La Jolla, CA 92037 (address) — Principal Executive Offices
  • Ibex SpinCo, Inc. (company) — Former Company Name

FAQ

What is the primary purpose of this 8-K filing for Inhibrx Biosciences, Inc.?

The primary purpose of this 8-K filing is for Regulation FD disclosures and to report financial statements and exhibits.

When was this 8-K report filed?

This 8-K report was filed on June 17, 2024.

What is the principal executive office address for Inhibrx Biosciences, Inc.?

The principal executive office address is 11025 N. Torrey Pines Road, Suite 140, La Jolla, CA 92037.

What was Inhibrx Biosciences, Inc.'s former company name?

Inhibrx Biosciences, Inc.'s former company name was Ibex SpinCo, Inc.

In which state is Inhibrx Biosciences, Inc. incorporated?

Inhibrx Biosciences, Inc. is incorporated in Delaware.

Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-06-17 16:03:05

Key Financial Figures

  • $0.0001 — ich registered Common Stock, par value $0.0001 per share INBX The Nasdaq Global Market

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 17, 2024, Inhibrx Biosciences, Inc. (the "Company") posted an updated copy of its corporate presentation to the "Investors" tab of its website at www.inhibrx.com. The presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. The Company from time to time presents and/or distributes the presentation to the investment community during conferences and meetings to provide updates and summaries of its business. The Company undertakes no obligation to update, supplement, or amend the materials attached hereto as Exhibit 99.1. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 17, 2024 INHIBRX BIOSCIENCES, INC. By: /s/ Kelly Deck Name: Kelly Deck Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.